Through all of the information to date it is very obvious that 1. Sanofi and the medical community read these studies as 'non conclusive' 2. Sanofi did not come out and classify the studies as false and untrue 3. Sanofi and all parties acknowledge the fact that this needs to be further investigated. 4. Due process will determine valility, or not.
This is not going away tomorrow or the next day. Unfortunately time will tell, new studies will be made and from that a sound decision will be made as to the direction and future. That is pretty much it, take it or leave (sell) it.
All big pharmas have unresolved issues, SNY's problem here is no show stopper. Rather it's most likely no big problem at all. Owning big pharma companies has risks and that's why it's best to hold a number of them and not to panic at the first shout of "the sky is falling"
It's somewhat akin to holding oil companies, one has to hope their wells come in and don't prematurely run dry.